Overview

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1 administered by intravenous (IV) infusion.

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab